Our innovative products and technologies define a new era in current and future diagnostic and therapeutic radiopharmaceuticals.
We lead the way in producing stable, reliable, domestically-sourced, environmentally-friendly radioisotope supply to meet critical patient healthcare needs and advance clinical research.
We are a recognized, emerging global leader with a proven track record and strong vision for the future of radiopharmaceuticals. Our innovation-driven technology is transforming the landscape for medical radioisotope production and distribution around the world.
First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of NeuroblastomaRead More >
NorthStar Medical Radioisotopes Executes Supply Agreement with Bayer for Therapeutic Radioisotope Actinium‐225 (Ac‐225)Read More >
NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)Read More >